web analytics
November 30, 2015 / 18 Kislev, 5776
At a Glance
News & Views
Sponsored Post

Israeli Anti-Nausea Pill for Cancer Patients Passes Clinical Trial

JewishPress Logo

Israel’s RedHill Biopharma announced success last week in a major clinical trial of a new drug to prevent nausea in cancer patients.

The once-a-day pill RHB-102, which has now passed a trial corresponding to a Phase III clinical trial, will compete with leading anti-nausea drug Zofran, made by GlaxoSmithKline, which is taken several times a day.

Redhill will apply to the FDA for a pre-New Drug Application hearing for market approval in a few weeks.

Anti-nausea medications are estimated to be worth $2 billion around the world, according to a report in Globes online business news.

About the Author: Malkah Fleisher is a graduate of Cardozo Law School in New York City. She is an editor/staff writer at JewishPress.com and co-hosts a weekly Israeli FM radio show. Malkah lives with her husband and two children on the Mount of Olives in Jerusalem.

If you don't see your comment after publishing it, refresh the page.

Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.

If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.

No Responses to “Israeli Anti-Nausea Pill for Cancer Patients Passes Clinical Trial”

Comments are closed.

Current Top Story
Israel's PM Benjamin Netanyahu and wife Sarah board the plane to head for Paris conference.
World Leaders Gather for ‘COP-21 Paris 2015’ Climate Change Conference

Printed from: http://www.jewishpress.com/news/breaking-news/israeli-anti-nausea-pill-for-cancer-patients-passes-clinical-trial/2012/04/24/

Scan this QR code to visit this page online: